Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s New Glaucoma Drug Zioptan Faces Formidable Market Challenge

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S. approval of the prostaglandin analogue adds to Merck’s ophthalmology portfolio, but it remains to be seen whether being preservative free confers tafluprost an advantage in a field that includes generics of the blockbuster Pfizer drug Xalatan.

You may also be interested in...

Sucampo Puts 40 Reps Behind Rescula Launch As it Seeks Revitalization

Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.

The New Ophthalmic Drug Players

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind.

Consolidated Alcon Eye Division Has Key Role In Maintaining Novartis’ Growth

Like many other big pharma companies, Novartis AG faces an imminent patent cliff, with blood pressure blockbuster Diovan (valsartan), among other products, due to lose patent protection soon.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts